Detailed paper information

Back to list

Paper title Comparison of New-Generation Double-Layer Micromesh Carotid Stent-System versus Carotid Self-expanding Hybrid Stent System in Symptomatic Carotid Artery Stenosis
Paper code P61
  1. Philipp Gruber Kantonsspital Aarau AG Speaker
  2. Timo Kahles Kantonsspital Aarau AG
  3. Jatta Berberat Kantonsspital Aarau
  4. Javier Anon Department of Neuroradiology, Kantonsspital Aarau, Aarau, Switzerland
  5. Michael Diepers Kantonsspital Aarau
  6. Krassen Nedeltchev Kantonsspital Aarau
  7. Luca Remonda Kantonsspital Aarau AG
Form of presentation Poster
  • SSNR-Neuroradiology
Abstract text Objective: Carotid artery stenosis is a relevant cause of ischemic stroke. Carotid artery stenting is an emerging alternative treatment option to surgical carotid endarterectomy. Several carotid stent-systems with different stent designs are available. CASPER (MicroVention, Inc., USA) – a double-layer micromesh carotid stent-system designed to prevent peri-procedural embolic release – belongs to the latest generation of carotid stent system. The aim of this study was to assess efficacy and safety of CASPER compared to a carotid self-expending hybrid stent system (Invatec Cristallo Ideal, Medtronic, USA) (Cristallo) in symptomatic carotid artery stenosis (sCS).
Method: A single-center, open-label, retrospective cohort study of 57 consecutive patients with proven sCS between 01/2014–08/2017 executed at a tertiary stroke center in Switzerland. Outcome measures were i) good clinical outcome at 90 days (mRS 0-2), ii) peri-procedural complications and ischemic events iii) re-occlusion rate and iiii) mortality within 30 days.
Results: 22 patients (23% women, median age 75 years (interquartile range (IQR) 71-80) were treated with CASPER, 35 patients (29% women, median age 71 years (IQR 63-76) years) with Cristallo. In both groups, pre-treatment carotid stenosis had similar median NASCET score of 80%. Successful deployment was achieved in all cases without technical failure and similar re-occlusion rates and mortality rate within 30 days. Clinical outcome was similarly beneficial in both groups. In the Cristallo group peri-procedural ischemic event was insignificantly higher (3 vs 0; p=0.16).
Conclusion: CASPER and Cristallo demonstrate to be similarly effective and safe in symptomatic carotid artery stenosis.